A New Hope in Alzheimer's Treatment; Lecanemab

Abstract

Lecanemab's apparent effectiveness follows years of disillusionment with earlier, comparable medications that were meant to delay or stop the course of Alzheimer's disease. It contains monoclonal antibodies that were created in laboratories with the goal of purging the brain of a material called as beta-amyloid, exactly like a lot of those other medicines. People with Alzheimer's disease tend to have an accumulation of beta-amyloid in their brains, which leads to the development of the sticky plaques that have come to be associated with the condition. As a result of this, the objective of his research paper is to investigate background information about the drug lecanemab. In addition to this, the study offers information regarding the approval procedure for lecanemab, the drug's mode of action, and, lastly, the most recent discoveries.